PGEN - Precigen, Inc.
Precigen (NASDAQ: PGEN - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk. Institutional and Insider Ownership 33.5% of Precigen shares are
Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Volatility and Risk Precigen has a beta of
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
Precigen just received an FDA "platform technology designation" for AdenoVerse, something that validates its versatility and accelerates its pipeline. PAPZIMEOS, the first FDA-approved product from AdenoVerse, is now the first-line standard of care for RRP with rapid payer coverage and strong uptake. PGEN targets a $2B peak global sales opportunity, with EMA approval for PAPZIMEOS potentially doubling the addressable market by year-end or early 2027.
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
Precigen, Inc. (NASDAQ: PGEN - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $8.04 and last traded at $7.89, with a volume of 5323560 shares. The stock had previously closed at $7.70. Analyst Upgrades and Downgrades PGEN has been the subject of a
Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®.
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Precigen (NASDAQ: PGEN - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation. Profitability This table compares Celldex Therapeutics and Precigen's
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
Legal and General Group Plc purchased a new stake in Precigen, Inc. (NASDAQ: PGEN) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 128,048 shares of the biotechnology company's stock, valued at approximately $730,000. A number of other hedge funds have
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Biotech in the News: The Longview The Company's New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis (RRP), is Delivering Strong Commercial Traction While Highlighting the Broader Potential of Its Proprietary AdenoVerse Therapeutic Platform in HPV-Associated Cancers GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability.
Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.
Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Precigen surged 266% on PAPZIMEOS FDA approval but now trades at a premium valuation near $2.24 billion. PAPZIMEOS, the sole revenue driver, reached $53.1 million in Q2 with COGS being just around $2.8 million. PGEN's pipeline faces stiff competition, with most candidates showing weaker efficacy than approved or late-stage rivals.